CB5138-3 / CohBar - LARVOL DELTA

CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire) - "Recent Updates and Second Quarter 2022 Highlights IND Filing for CB5138-3 on Track: The company continued to advance CB5138-3, its lead program for Idiopathic Pulmonary Fibrosis (IPF), through IND-enabling studies and formulation activities. In the second half of 2023, CohBar expects to submit an Investigational New Drug Application (IND) for CB5138-3 to the US Food and Drug Administration."

IND • Idiopathic Pulmonary Fibrosis

CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) - "CohBar has aligned its resources to focus on three main areas: (1) the development of its novel peptide analog, CB5138-3, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition to the ongoing IND-enabling studies, the company is focused on optimizing drug delivery to increase the likelihood of success in the clinic for this hard-to-treat patient population. The IND for this program is now expected to be submitted in the second half of 2023; (2) the discovery and development of additional novel peptide families using the company’s novel Mito+ platform; and (3) the pursuit of a partnership for further development of CB4211."

IND • Idiopathic Pulmonary Fibrosis

[VIRTUAL] Revealing Breakthrough Mitochondrial Science for IPF (IPF Summit 2021) - "Synopsis Analyze how CohBar is harnessing the power of mitochondria peptides to target a wide range of chronic and age-related diseases associated with mitochondrial dysfunction, including IPF Review CohBar’s clinical candidate, CB5138-3, in development for IPF which has demonstrated positive effects including reduction of fibrosis, inflammation, and collagen deposition. Discuss other potential antifibrotic indications for CB5138-3"

Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Metabolic Disorders

CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics (SeekingAlpha) - “CohBar is in a reasonable financial position…2021's cash burn isn't expected to change drastically with a potential 10-15% increase expected for the IND-enabling activities of CB5138-3 - IPF….CB5138 is CohBar's second-leading therapeutic approaching clinical-phase expected to commence in 2022….CohBar expects to field an IND in 2022.”

Financing • IND • New trial • Idiopathic Pulmonary Fibrosis

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) - "...'nominated a CB5138 Analog as our second clinical candidate based on positive preclinical studies during the last quarter'....CohBar has initiated IND-enabling activities for CB5138-3..."

Preclinical • Idiopathic Pulmonary Fibrosis